Robust growth in Hospitals, aided by focus specialties
Apollo HealthCo reports positive PAT of Rs 32 Crores vs Rs (28) Crores of PAT Loss in Q3 FY24
Q3 Consolidated Revenues grew 14% YoY to Rs 5,527 Crores
Q3 Consolidated EBITDA grew 24% YoY to Rs 762 Crores
Q3 Consolidated PAT grew 52% YoY to Rs 372 Crores
On track to add 3,512 beds over a period of 3 to 4 years, beginning FY26
Apollo Hospitals achieved a milestone in cardiac care, completing over 1000 robotic cardiac surgeries across Bangalore & Chennai
Apollo Hospitals partnered with Microsoft to advance healthcare through AI and digital innovation focussing on disease progression, and genomics
Apollo Hospitals declares an Interim Dividend of Rs 9 per share
Dr. Prathap C Reddy, Chairman, Apollo Hospitals Enterprise Ltd. said,
At Apollo Hospitals, we have always measured success by the lives we touch and the impact we create for a healthier nation. With Q3 FY25 revenues rising by 14% to ₹ 5,527 crores and EBITDA by 24% to ₹ 762 crores, our performance is a testament to our commitment of a healthier India by bringing cutting-edge technologies to everyone who needs it. We are on track to add 3,512 beds across 11 locations over 3 to 4 years beginning FY26. The results reflect our growth story that underlines our purpose of healing India and touching more than a billion lives. From Mumbai to Varanasi and Chennai to Gurugram, we are committed to ensuring that quality healthcare is not a privilege but a fundamental right for all.
Our strategic partnership with Microsoft is accelerating our AI-driven healthcare transformation, including innovation in disease progression, and genomics. By collaborating with the University of Leicester, we are equipping the next generation of healthcare professionals with unmatched skills. Taking our impact global, Apollo Hospitals Enterprise Limited (AHEL) signed a landmark Memorandum of Understanding (MoU) with Mayapada Healthcare Group, Indonesia to transform the region`s healthcare landscape by enhancing medical capabilities, clinical programs, and operational excellence in oncology, cardiology, neurology, and transplant surgery.
At Apollo Hospitals, we recognise the rising burden of cancer and launched Unify to Notify campaign towards classifying cancer as a notifiable disease. Our pursuit of enhancing our clinical excellence continues with landmark surgeries and treatments at our hospitals across India. Apollo Hospitals, Chennai achieved a remarkable benchmark in cardiac care by completing 500 robotic cardiac surgeries. Apollo Hospitals, Bangalore performed a robotic knee replacement surgery on a 17-year-old boy, the youngest reported case in the world, who was struggling with severe Avascular Necrosis.
As we look ahead, we are confident about our plans to creat a sustainable impact and value to ˜Heal in India` and ˜Heal by India` with world-class healthcare and cutting-edge innovation not just for India but for the world.
Q3 FY25 CONSOLIDATED RESULTS
REVENUE
Q3 FY25 Revenues grew to Rs. 5,527 Crores; 14% YoY growth
- Healthcare Services (HCS) Revenue at Rs. 2,785 Crore; 13% YoY growth
- AHLL: Revenues at Rs. 390 Crores; 15% YoY growth
- Apollo HealthCo: Pharmacy Distribution & Digital Health Revenues at Rs. 2,352 Crores; 15% YoY growth
- GMV of Apollo 24/7 at Rs. 760 Crores
EBITDA
Q3 FY25 Consolidated EBITDA stood at Rs. 762 Crores; 24% YoY growth
- Healthcare Services (HCS) EBITDA at Rs. 671 Crores; YoY growth of 14%
- AHLL EBITDA at Rs. 34 Crores; YoY growth of 32%
- Apollo HealthCo: Pharmacy distribution & Digital health EBITDA at Rs. 57 Crores
PAT
Q3 FY25 Consolidated PAT Rs. 372 Crores, compared to Rs. 245 Crores in Q3 FY24; 52% YoY growth
- Healthcare Services (HCS) PAT at Rs. 348 Crore; YoY growth of 21%
YTD Dec FY25 CONSOLIDATED RESULTS
- Healthcare Services (HCS) PAT at Rs. 1,041 Crore; YoY growth of 20%
Financial Performance – Q3 FY25
Consolidated Q3 FY25 Performance
- Revenues at Rs.55,269 mn vs Rs.48,506 mn in Q3 FY24; growth of 14% YoY
- EBITDA at Rs.7,615 mn vs Rs.6,137 mn in Q3 FY24. This is after Apollo 24/7 cost of Rs 1,405 mn in the quarter (including Rs 268 mn non-cash ESOP charge) vs Rs 1,557 mn in Q3 FY24.
- Reported PAT at Rs.3,723 mn vs Rs.2,453 mn in Q3 FY24
- Diluted EPS of Rs.25.89 per share in Q3 FY25 (not annualized)